Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Bankable Feasibility Study

23 Jun 2006 09:59

Ovoca Gold PLC23 June 2006 OVOCA GOLD PLC Ovoca Starts Bankable Feasibility Study on the Goltsovoye Silver Deposit, Russia Friday, 23 June 2006 Ovoca Gold Plc (AIM: OVG; IEX: OVX) is pleased to announce that it has appointedWardell Armstrong to conduct a Bankable Feasibility Study on the 74 millionounce Goltsovoye silver deposit in the Magadan Region of Russia to commence inthe first week of July 2006. Following the recent acquisition of a 78% equity interest in the Russian companyCJSC Ayax, holder of a mining license for the Goltsovoye silver deposit in theMagadan Region in the east of Russia, Ovoca has now engaged Wardell ArmstrongInternational Limited to complete a bankable feasibility study for thedevelopment of the deposit to be completed by the first quarter of 2007. TheWardell team will commence work on site during the first week of July 2006 A confirmatory core drilling programme, geotechnical and hydrological drillingprogramme will shortly commence under the supervision of the consultant and willsupplement the study. The Goltsovoye deposit which has reserves of 74 millionounces of silver approved as C1 and C2 under the Russian standard for resourceclassification will during the study be converted to the western JORC standardfor resource and reserve classification. Following completion of the bankable study, Ovoca plans to rapidly move intomine construction during 2008. On completion, the Goltsovoye mine, Ovoca Gold will develop into a mid-tierprecious metal producer with additional advanced exploration projects in theKola Region of northwest Russia bring additional resources for futuredevelopment. Ovoca Gold Plc is an international company developing and exploring precious and base metals in Russia, Sweden and Ireland quoted in London (OVG.L) and Dublin (OVX.IR). For further information please visit www.ovocagold.com or contact: Simon Beardsmore - Ovoca Gold Nick Bias Buck Bias (UK PR) Tel: +44 (0)207 7397 8159 Tel: +44 (0)7887 920 530 Email: simon.beardsmore@ovocagold.com Email:nick@buckbias.com /Mr John Frain - Davy Broker) Richard Chase- Ambrian Partners+44 (0)207 776 6461 Tel: +353 (0)1 614 8761 Email: richard.chase@ambrian.com Email: john.frain@davy.ie 23 June, 2006 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jul 20227:00 amRNSCompletion of Enrollment in Phase II Study
30th Jun 20227:00 amRNSAnnual Financial Report
7th Mar 20229:00 amRNSStatement re Russian Business Operations
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20223:30 pmRNSRussian Marketing Authorisation for Orenetide
31st Jan 20227:00 amRNSBoard Changes and Update
30th Dec 20217:00 amRNSDirectorate Change
4th Nov 20213:53 pmRNSHolding(s) in Company
4th Nov 20213:50 pmRNSDirector/PDMR Shareholding
4th Nov 20213:46 pmRNSBoard Change
14th Sep 20217:00 amRNSInterim Results
29th Jul 20215:00 pmRNSResult of AGM
24th Jun 20217:00 amRNSAnnual Report and Notice of AGM
10th Mar 20217:00 amRNSMigration of Participating Securities
16th Feb 20212:00 pmRNSResult of EGM
29th Jan 20217:00 amRNSFirst Patient Enrolled in Phase II Study - BP-101
25th Jan 20213:30 pmRNSNotice of EGM
5th Jan 20217:00 amRNSRe-Filing of Marketing Authorisation Application
17th Dec 20202:45 pmRNSResult of AGM
27th Nov 20203:08 pmRNSNotice of AGM
9th Oct 20207:00 amRNSAppointment of Chief Business Officer
2nd Oct 202011:06 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSUpdate re Russian Marketing Authorisation
28th Sep 20207:00 amRNSDeath of a Director
21st Sep 20207:00 amRNSInterim Results
14th Aug 202011:05 amRNSSecond Price Monitoring Extn
14th Aug 202011:00 amRNSPrice Monitoring Extension
26th Jun 20207:00 amRNSAnnual Report
14th Apr 20202:05 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSAcquisition of Remaining Minority Interest in IVIX
7th Nov 201912:45 pmRNSAttendance at Bio-Europe Conference
16th Sep 20197:00 amRNSInterim Results
12th Sep 20197:00 amRNSFiling of Marketing Authorisation Application
28th Aug 20197:00 amRNSDirectorate Change
8th Aug 20194:14 pmRNSResult of AGM
8th Aug 20199:05 amRNSSecond Price Monitoring Extn
8th Aug 20199:00 amRNSPrice Monitoring Extension
8th Aug 20197:00 amRNSAGM Statement
26th Jul 20197:00 amRNSDirectorate Change
25th Jul 20194:41 pmRNSSecond Price Monitoring Extn
25th Jul 20194:35 pmRNSPrice Monitoring Extension
28th Jun 20197:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20197:00 amRNSUS and EU Clinical Development Plans
29th Mar 20197:00 amRNSDirector/PDMR Shareholding
27th Mar 20197:00 amRNSOperational Update & Additional Investment in IVIX

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.